2.85
price down icon1.72%   -0.05
after-market Dopo l'orario di chiusura: 2.81 -0.04 -1.40%
loading

Savara Inc Borsa (SVRA) Ultime notizie

pulisher
Apr 03, 2025

Health Check: How Prudently Does Savara (NASDAQ:SVRA) Use Debt? - simplywall.st

Apr 03, 2025
pulisher
Apr 02, 2025

Savara Reports 2024 Financial Results and Provides Updates on MOLBREEVI Progress - MSN

Apr 02, 2025
pulisher
Apr 02, 2025

Savara Secures $200 Million Loan Agreement with Hercules Capital - MSN

Apr 02, 2025
pulisher
Apr 01, 2025

Savara director David Ramsay acquires $416,250 in common stock By Investing.com - Investing.com Australia

Apr 01, 2025
pulisher
Apr 01, 2025

Savara Insider Bought Shares Worth $416,250, According to a Recent SEC Filing - MarketScreener

Apr 01, 2025
pulisher
Apr 01, 2025

Savara director David Ramsay acquires $416,250 in common stock - Investing.com India

Apr 01, 2025
pulisher
Apr 01, 2025

Savara Completes BLA Submission for MOLBREEVI to Treat aPAP - MSN

Apr 01, 2025
pulisher
Mar 31, 2025

Savara’s SWOT analysis: rare disease biotech stock eyes FDA approval By Investing.com - Investing.com South Africa

Mar 31, 2025
pulisher
Mar 31, 2025

Savara IncTerminates ATM Agreement With Evercore Effective April 2, 2025SEC Filing - MarketScreener

Mar 31, 2025
pulisher
Mar 31, 2025

SAVARA Earnings Preview: Recent $SVRA Insider Trading, Hedge Fund Activity, and More - Nasdaq

Mar 31, 2025
pulisher
Mar 31, 2025

Savara Inc ends sales agreement with Evercore - Investing.com

Mar 31, 2025
pulisher
Mar 31, 2025

Savara’s SWOT analysis: rare disease biotech stock eyes FDA approval - Investing.com India

Mar 31, 2025
pulisher
Mar 31, 2025

Swiss National Bank Decreases Stock Holdings in Savara Inc (NASDAQ:SVRA) - Defense World

Mar 31, 2025
pulisher
Mar 31, 2025

What is HC Wainwright’s Estimate for Savara Q1 Earnings? - Defense World

Mar 31, 2025
pulisher
Mar 30, 2025

HC Wainwright Reaffirms Buy Rating for Savara (NASDAQ:SVRA) - Defense World

Mar 30, 2025
pulisher
Mar 28, 2025

Savara enters loan and security agreement with Hercules Capital - MSN

Mar 28, 2025
pulisher
Mar 28, 2025

Savara stock holds Buy rating, $6 target from H.C. Wainwright By Investing.com - Investing.com Australia

Mar 28, 2025
pulisher
Mar 28, 2025

Savara stock holds Buy rating, $6 target from H.C. Wainwright - Investing.com India

Mar 28, 2025
pulisher
Mar 28, 2025

Charles Schwab Investment Management Inc. Grows Position in Savara Inc (NASDAQ:SVRA) - Defense World

Mar 28, 2025
pulisher
Mar 27, 2025

Nkarta to lay off 34% of staff; Savara’s debt financing deal - Endpoints News

Mar 27, 2025
pulisher
Mar 27, 2025

Savara Inc. (SVRA) reports earnings - Quartz

Mar 27, 2025
pulisher
Mar 27, 2025

Savara Reports Fourth Quarter and Year End 2024 Financial Results and Provides Business Update - Joplin Globe

Mar 27, 2025
pulisher
Mar 27, 2025

Breakthrough: Savara Advances First-Ever aPAP Treatment with FDA Filing, Reports $196M Cash Position - Stock Titan

Mar 27, 2025
pulisher
Mar 27, 2025

JMP maintains $9 target on Savara stock, sees FDA nod By Investing.com - Investing.com South Africa

Mar 27, 2025
pulisher
Mar 27, 2025

JMP maintains $9 target on Savara stock, sees FDA nod - Investing.com India

Mar 27, 2025
pulisher
Mar 26, 2025

Savara secures $200M loan to support respiratory drug launch By Investing.com - Investing.com South Africa

Mar 26, 2025
pulisher
Mar 26, 2025

Savara secures $200M loan to support respiratory drug launch - Investing.com India

Mar 26, 2025
pulisher
Mar 26, 2025

Savara Gets Up to $200 Million Loan From Hercules Capital - Marketscreener.com

Mar 26, 2025
pulisher
Mar 26, 2025

Savara Enters Into Non-Dilutive Debt Financing for up to $200M With Hercules Capital - Bluefield Daily Telegraph

Mar 26, 2025
pulisher
Mar 26, 2025

Major Financial Boost: Savara Lands $200M Debt Deal as FDA Decision Approaches - Stock Titan

Mar 26, 2025
pulisher
Mar 26, 2025

Savara submits FDA application for aPAP therapy MOLBREEVI - Investing.com

Mar 26, 2025
pulisher
Mar 26, 2025

Savara Completes Submission Of The Biologics License Application (BLA) To The U.S. Food And Drug Administration (FDA) For MOLBREEVI As A Treatment For Autoimmune Pulmonary Alveolar Proteinosis (aPAP) - MarketScreener

Mar 26, 2025
pulisher
Mar 26, 2025

Savara Completes Submission of the Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) for MOLBREEVI* as a Treatment for Autoimmune Pulmonary Alveolar Proteinosis (aPAP) - Business Wire

Mar 26, 2025
pulisher
Mar 26, 2025

Bank of New York Mellon Corp Purchases 17,870 Shares of Savara Inc (NASDAQ:SVRA) - Defense World

Mar 26, 2025
pulisher
Mar 26, 2025

Breakthrough: First Treatment for Rare Lung Disease aPAP Heads to FDA Review - Stock Titan

Mar 26, 2025
pulisher
Mar 24, 2025

Savara Inc (NASDAQ: SVRA) Stock: Investors Need To Know This - Stocks Register

Mar 24, 2025
pulisher
Mar 24, 2025

Victory Capital Management Inc. Reduces Stock Holdings in Savara Inc (NASDAQ:SVRA) - Defense World

Mar 24, 2025
pulisher
Mar 21, 2025

Savara Inc expected to post a loss of 11 cents a shareEarnings Preview - TradingView

Mar 21, 2025
pulisher
Mar 20, 2025

Savara Inc (NASDAQ:SVRA) Receives $8.83 Consensus Price Target from Analysts - Defense World

Mar 20, 2025
pulisher
Mar 18, 2025

Savara Inc. to Present at Leerink Global Healthcare Conference - MSN

Mar 18, 2025
pulisher
Mar 17, 2025

Breakthrough Phase 3 Results: New Treatment Reduces Lung Procedures in Rare Disease Patients - StockTitan

Mar 17, 2025
pulisher
Mar 13, 2025

Savara Inc. Launches Convenient DBS Test for Diagnosing Rare Lung Disease - MSN

Mar 13, 2025
pulisher
Mar 10, 2025

Oppenheimer & Co. Inc. Decreases Stock Holdings in Savara Inc (NASDAQ:SVRA) - Defense World

Mar 10, 2025
pulisher
Mar 09, 2025

Rhumbline Advisers Purchases 9,041 Shares of Savara Inc (NASDAQ:SVRA) - Defense World

Mar 09, 2025
$60.26
price down icon 10.70%
$69.18
price down icon 5.66%
$17.36
price down icon 8.20%
$31.11
price down icon 2.14%
$88.05
price down icon 4.30%
biotechnology ONC
$238.51
price down icon 9.76%
Capitalizzazione:     |  Volume (24 ore):